Cereno Scientific AB (OSTO:CRNO B) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cereno Scientific AB's Free Cash Flow for the three months ended in Dec. 2024 was kr-56.26 Mil. Cereno Scientific AB's Revenue for the three months ended in Dec. 2024 was kr0.00 Mil. Therefore, Cereno Scientific AB's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Cereno Scientific AB's current FCF Yield % is -8.21%.

The historical rank and industry rank for Cereno Scientific AB's FCF Margin % or its related term are showing as below:

OSTO:CRNO B's FCF Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.735
* Ranked among companies with meaningful FCF Margin % only.

Cereno Scientific AB FCF Margin % Historical Data

The historical data trend for Cereno Scientific AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB FCF Margin % Chart

Cereno Scientific AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

Cereno Scientific AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cereno Scientific AB's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cereno Scientific AB's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Cereno Scientific AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cereno Scientific AB's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-188.196	/	0
	=	%

Cereno Scientific AB's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-56.264	/	0
	=	%

Cereno Scientific AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cereno Scientific AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

4A1:Germany

Address

BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83

Website

https://www.cerenoscientific.se

Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines